Chemokines are a family of small basic proteins which induce the directed migration of cells, notably leucocytes, by binding to specific GPCRs (G-protein-coupled receptors ). Both chemokines and their receptors have been implicated in a host of clinically important diseases, leading to the notion that antagonism of the chemokine-chemokine receptor network may be therapeutically advantageous. Consequently, considerable effort has been put into the development of small-molecule antagonists of chemokine receptors and several such compounds have been described in the literature. One curious by-product of this activity has been the description of several small-molecule agonists of the receptors, which are typically discovered following the optimization of lead antagonists. In this review we discuss these findings and conclude that these smallmolecule agonists might be exploited to further our understanding of the molecular mechanisms by which chemokine receptors are activated.
Introduction
Chemokines are a family of predominantly basic lowmolecular-mass proteins numbering over 40 in humans [1] . The term chemokine has its roots in the abridging of the earlier term 'chemotactic cytokine' and describes their ability to induce the directed migration or chemotaxis of cells, notably leucocytes. Selective recruitment of leucocytes under both homoeostatic and inflammatory processes is governed by chemokines which can be conveniently defined as belonging to one of two major families depending upon the positioning of two conserved N-terminal cysteine residues within the primary structure [2] . Chemokines denoted as belonging to the CXC subclass have a single amino acid interposed between the two cysteine residues and typically attract neutrophils and T-lymphocytes. In CC chemokines, the two conserved cysteine residues are adjacent, and members of this family have a broader spectrum of action, recruiting monocytes, lymphocytes, basophils and eosinophils. Two minor classes also exist, namely the CX 3 C and C chemokine families which have only three members between them. Despite only limited homology between chemokines at the amino acid level, NMR and crystallographic studies have revealed that chemokines share a common protein fold, known as a 'Greek key' motif, in which three antiparallel β-pleated sheets are overlaid by a C-terminal α-helix. The conserved cysteine residues within the primary sequence give stability to the tertiary structure via intermolecular disulfide bonds.
Chemokines exert their effects on leucocytes by binding to GPCRs (G-protein-coupled receptors) expressed on the leucocyte cell surface [3, 4] (Table 1) . These receptors belong to Class A of the GPCR superfamily which are typically 340-380 amino acids in length and contain the molecular signature of seven TM (transmembrane) spanning helices. Like all GPCRs, chemokine receptors transduce signals via the activation of heterotrimeric G proteins, in particular those containing pertussis toxin-sensitive Gα i subunits [5] . Research into chemokines and their receptors has been fuelled by the finding that two chemokine receptors expressed on T-cells named CCR5 and CXCR4 serve in conjunction with CD4 as co-receptors for the cellular entry of HIV-1 [6] . This, coupled with the correlation between inadvertent or excessive production of chemokines and the inflammatory components of many clinically important diseases, has interested the pharmaceutical industry in the possibility of antagonizing the activity of chemokines as a potential therapeutic avenue.
Since an estimated 50% of modern medicines act upon GPCRs, there is some cause for optimism [7] . A survey of both the patent and scientific literature reveals that highthroughput screening of chemical libraries by the pharmaceutical industry has identified a large number of potent receptor antagonists. In addition, considerable effort has been undertaken in parallel by several academic groups to determine how the chemokines themselves interact with their receptors. Putting the pieces of these jigsaws together, we are now reaching a position in which we are beginning 
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Ligand binding and activation of chemokine receptors
Early in vitro studies in which the N-termini of chemokine receptors were exchanged to generate chimaeric constructs, supported the notion that ligand binding and receptor activation typically occurs via a two-step model [8, 9] . In this model, the chemokine is initially tethered by a high-affinity interaction with the N-terminus of the receptor. This orients the chemokine for activation of the receptor in the second step and is also supported by NMR studies examining the binding of chemokine to peptide mimics of the receptor N-terminus [10, 11] . Of particular importance in the activation step is the N-terminus of the chemokine. Truncation or chemical modification of this region often results in the generation of antagonists, i.e. chemokines able to bind to their receptor, but unable to activate it [12, 13] . In the absence of a crystal structure of a chemokine receptor, the intricacies of receptor activation are unclear, and much trust has been placed in homology modelling using the crystal structure of bovine rhodopsin as a template, the only GPCR to date for which a high-resolution structure exists [14] . Typically, chemokine receptors possess around 20% similarity to rhodopsin, which, as one would expect from a superfamily of serpentine receptors, is predominantly between the TM helices. Indeed, it is these that are generally modelled rather than the extracellular domains for which no supporting data exist. Homology modelling of the chemokine receptor CCR5, coupled with site-directed mutagenesis, supported the existence of hydrophobic interactions between residues in TM helices 2 and 3, held together in the inactive conformation of the receptor [15] [16] [17] . Perturbation of these interactions by the N-terminus of the CCR5-specific chemokine CCL3 is postulated to lead to the stabilization of an active receptor confirmation and Gprotein recruitment and subsequent signalling ( Figure 1A ).
The eagerly anticipated arrival of small-molecule antagonists of chemokine receptors
The arrival of a specific small-molecule antagonist of chemokine receptors was heralded by the description of 4-hydroxypiperidine compounds with specific activity at CCR1 [18] . These compounds had nanomolar affinity for their target and were identified by high-throughput screening on the basis of their ability to displace iodinated ligand from the receptor. These molecules were quickly followed in the literature by a growing army of small-molecule antagonists of both CC and CXC chemokine receptors (reviewed in [19] ), including the respective CXCR4 and CCR5 antagonists AMD3100 and TAK-779 which showed in vitro efficacy in blocking HIV-1 entry [20, 21] . To date, few compounds have made it past the Phase II stage of clinical trials owing to a variety of issues, notably poor bioavailability, toxicity problems and a lack of efficacy [19] , although the CCR5 antagonist Miraviroc, developed by Pfizer scientists as an anti-HIV-1 therapy, shows promise [22] . Our own efforts in the laboratory have focused upon a particular compound named UCB 35625, a transisomer of a compound described by scientists from Banyu as possessing dual activity at the chemokine receptors CCR1 and CCR3 [23] . Despite observing nanomolar activity at both receptors, we were unable to efficiently displace ligand from either receptor, which argued against the dogma of the day that these compounds were competitive antagonists [24] . Moreover, we observed quite different pharmacological profiles at CCR1 and CCR3 with this single compound. Antagonist activity at CCR3 was found to be surmountable by excess ligand, whereas activity at CCR1 was insurmountable, suggesting subtle differences in its mode of action [24] . Since CCR1 and CCR3 shared most homology in the transmembrane [25] . Access to the interface of TM helices 2 and 3 is severely impeded by the compound, supporting the earlier cartoon.
helices, we postulated that the compound functioned by interacting with amino acids within a hydrophobic pocket composed of the TM helices and stabilizes the receptor in an inactive conformation, allowing ligand binding, but not signal transduction ( Figure 1B) .
We recently described the results of a mutagenesis study of CCR1 undertaken to directly examine this hypothesis. Out of a panel of 34 constructs containing point mutations directed against specific residues within the TM helices, we found three intrahelical residues, namely Tyr 41 , Tyr 113 and Glu 287 , that, when mutated, had no effect on migratory responses to the natural ligand CCL3, but conferred resistance to the antagonist [25] . Homology modelling of CCR1 using the rhodopsin crystal structure followed by manual docking of the compound to the intrahelical binding site supported our earlier hypothesis and suggested a key role for Glu 287 in forming an ionic interaction with the positively charged quaternary nitrogen of the compound. Interestingly, an acidic residue is conserved between several chemokine receptors in the homologous position and has been shown by similar mutagenesis studies to play a role in the binding of similarly charged antagonists of CCR2 and CCR5 [26, 27] . Analysis of our model suggests that access to the interface of TMs 2 and 3 is likely to be severely restricted by the presence of UCB35625 (Figures 1C and 1D ) a region previously suggested by others to interact with the chemokine receptor N-terminus during the process of receptor activation [15] . Since CCR1 and CCR3 share considerable homology in this region, it is likely that the antagonist-binding site is conserved between both receptors. Point mutagenesis of the homologous residues in CCR3, coupled with homology modelling, should be able to answer this question directly.
The question as to whether or not such antagonists act in a competitive manner has been answered to a large degree by the work of Watson et al. [28] , who, using a panel of wellcharacterized CCR5 antagonists in a comprehensive series of competitive binding assays, clearly showed that the compounds were allosteric rather than orthosteric modulators of receptor function. These are likely to produce a change in receptor conformation leading to the ligand displacement observed in vitro [28] . Indeed, as the authors of that study point out, given both the size of both chemokines and their receptors (approx. 10 and 35 kDa respectively) coupled with the fact that multiple distinct sites on both molecules are required for a productive interaction, it is quite difficult to imagine that steric hindrance of the interaction between both proteins by small-molecule antagonists is achievable [29, 30] . A subsequent study by scientists at Berlex employed a radiolabelled version of their CCR1 antagonist BX-471 to categorically show that, while the compound could displace the ligands CCL3 and CCL5 from the receptor, the reciprocal was untrue, showing beyond reasonable doubt that this smallmolecule antagonist also acts via an allosteric mechanism [31] .
The unexpected arrival of small-molecule agonists of chemokine receptors
Structure-activity optimization by three groups aimed at refining the potency of a variety of CCR3 antagonists has led to the curious finding that agonists, rather than antagonists, of the receptor were generated [32] [33] [34] . In each case, the potency of the small-molecule agonist has been several orders of magnitude lower than the parent natural ligand CCL11, regardless of the assay of receptor function employed. In the case of the novel pyrrolidinohydroquinazoline-based compounds described by scientists from Boehringer Ingelheim, a smallmolecule agonist named 8b (Figure 2 ), resulting from their structure-activity optimization of a lead compound named 4a, was able to induce intracellular calcium flux in human eosinophils, although micromolar concentrations, rather (8b) and its antagonist parent compound (4a) described by scientists from Boehringer Ingelheim [33] . Note the similarity between the structures of the agonist and antagonist, suggesting that a fine line divides either activity at CCR3.
than nanomolar concentrations, of the natural ligand CCL11 were required. Interestingly, response to the compound could be blocked by pre-administration of another small-molecule CCR3 antagonist RO320-2947/001 [35] , which itself had no such agonist activity. This suggests that both molecules bind to a similar site within the receptor and that there is a fine line dividing antagonism and agonism at CCR3.
Whether or not these findings are peculiar to CCR3 is an obvious question. More recently, there have been single reports of small-molecule agonists being uncovered in programmes designed to identify antagonists of the receptors CCR5, CCR8 and CXCR3 [36] [37] [38] . These smallmolecule antagonists have been shown to induce many of the downstream signalling pathways typical of the chemokines themselves, such as chemotaxis [37, 38] receptor internalization [36] and ERK (extracellular-signal-regulated kinase) phosphorylation [37] . The binding sites of these molecules within their receptor have not been elucidated, although in the case of the small-molecule CCR5 antagonist, in silico modelling suggests that they may bind within a pocket formed by TMs, akin to an antagonist [36] . It will be intriguing to test this hypothesis by site-directed mutagenesis of the receptor perhaps coupled with alternative approaches such as ab initio modelling of chemokine receptors [31, 39] . In the continued absence of hard data defining the threedimensional structure of GPCRs more homologous with chemokine receptors than rhodopsin, such an approach may give further clues about both the binding sites of small-molecule agonists and antagonists and also changes in conformation following their binding.
Summary
In the 30 years since the discovery of the first member of the chemokine family [40] , research has progressed at a breathtaking pace. A major driving force in this discovery process has been the finding that chemokines and their receptors are implicated in a host of clinically important diseases, making the GPCRs that mediate chemokine-induced signalling attractive therapeutic targets. Building on historical success in therapeutically targeting the GPCR superfamily, coupled with modern high-throughput screening methodologies, the literature is awash with the description of many specific potent compounds with efficacy in vitro.
One by-product of these huge efforts has been the recent trickle of small-molecule agonists emerging during lead optimization. Although perhaps of limited therapeutic use, in the current research climate of only a single high-resolution GPCR structure to work with, these small-molecule agonists show promise as useful investigative tools by which to dissect the mechanisms by which chemokine receptors are activated.
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